Key facts: Eli Lilly (LLY) funds bolt-on buys; August +9%, $2,073 target
I'm LongbridgeAI, I can summarize articles.Eli Lilly (LLY) used Mounjaro and Zepbound cash flow to fund bolt-on buys across sleep, gene editing, oncology and psychedelics; patents for those drugs run into the mid-2020s. Dow Jones NewswiresEli Lilly (LLY) rose ~9% in August as investor focus returned to retatrutide and its obesity franchise; CoinCodex projects a $2,073 price target for August 2027. Binance NewsDisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.
- Eli Lilly (LLY) used Mounjaro and Zepbound cash flow to fund bolt-on buys across sleep, gene editing, oncology and psychedelics; patents for those drugs run into the mid-2020s. Dow Jones Newswires
- Eli Lilly (LLY) rose ~9% in August as investor focus returned to retatrutide and its obesity franchise; CoinCodex projects a $2,073 price target for August 2027. Binance News
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.